Home/All Molecules/Sacubitril

Sacubitril Range

Comprehensive Sacubitril portfolio for Franchise & Manufacturing.

Category
sacubitril
Total Formulations
3
Available Forms
Tablets

Expand Your Business with Our Multiple Divisions


Browse Sacubitril portfolio by Dosage Form


The Cafoli Advantage for PCD Franchise & Manufacturing

WHO-GMP Quality

Every Sacubitril batch undergoes rigorous in-house and third-party testing, strictly adhering to WHO-GMP standards for efficacy and safety.

Quality Policy

Monopoly & Branding

Secure exclusive PCD franchise rights for your territory and benefit from our range of premium, marketing-driven product packaging.

Market Strategy

Sales Support

Enhance your sales with Cafoli’s complete kit of marketing materials, including visual aids, MR bags, catch covers, and product cards.

Marketing Tools

Sacubitril PCD Pharma Franchise

Sacubitril PCD Pharma Franchise Company

Cafoli Lifecare is a WHO-GMP certified Sacubitril PCD pharma franchise company offering a portfolio of 3 Sacubitril formulations across tablets. Every batch is manufactured at DCGI-approved facilities and supplied to franchise partners with district-level monopoly rights, ready-to-use promotional inputs and dependable stock availability.

What is Sacubitril?

Sacubitril is a neprilysin inhibitor, used in a fixed-dose combination with the angiotensin receptor blocker valsartan (an ARNI). Blocking neprilysin preserves natriuretic peptides, promoting vasodilatation and natriuresis, while valsartan blocks the renin-angiotensin system; the combination reduces cardiac preload and afterload in heart failure. The compound record can be reviewed on PubChem.

Therapeutic Applications

Chronic heart failure with reduced ejection fraction, where guideline-directed therapy now positions ARNI as a foundational pillar alongside beta-blockers, mineralocorticoid receptor antagonists and SGLT2 inhibitors. It is prescribed as sacubitril/valsartan, not as sacubitril alone.

Prescribed by: Cardiologists and heart-failure specialists are the principal prescribers of sacubitril/valsartan; consulting physicians continue therapy initiated by a cardiologist.

Why Sacubitril is a High-Potential Molecule for Distributors

Sacubitril/valsartan is one of the few genuinely guideline-changing cardiology molecules of the last decade and has moved from a second-line option to a foundational heart-failure therapy. India carries a very large and under-treated heart-failure population, and once a patient is stabilised on an ARNI the therapy is continued indefinitely, giving exceptionally high prescription retention. It is a specialist-driven, premium-value line, so volumes are modest compared with a statin but per-unit value and repeat rates are high, which suits a distributor building a serious cardiology portfolio.

Why Choose Cafoli Lifecare

Cafoli Lifecare offers its Sacubitril franchise partners genuine monopoly rights for their allotted district or territory, products manufactured in WHO-GMP certified, DCGI-approved units, and complete promotional support — visual aids, MR bags, sample packs, product cards and doctor gifting. With 1000+ channel partners across India, on-time dispatch and transparent net rates, we make it straightforward to build a profitable Sacubitril business in your region.

References

  1. PubChem – Sacubitril compound record, US National Library of Medicine
  2. PubMed – clinical literature on Sacubitril, NCBI

Aceclofenac in Modern Clinical Practice

Our formulations of Sacubitril find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to:


FAQ about Sacubitril in PCD Franchise

Start Your Sacubitril Franchise with Cafoli Lifecare

Ready to take monopoly rights for Sacubitril in your district? Talk to our franchise team for net rates, packing details and the current availability list. Call 9518447302 or email info@cafoli.in.

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions (FAQs)

Cafoli Lifecare offers 3 Sacubitril formulations in tablets. The current list with packing and net rates is shared with registered franchise enquiries.

Yes. Monopoly rights for the Sacubitril range are allotted district-wise on a first-come basis and are confirmed in your franchise agreement, so no other Cafoli partner sells the same brands in your territory.

Cardiologists and heart-failure specialists are the principal prescribers of sacubitril/valsartan; consulting physicians continue therapy initiated by a cardiologist.

Sacubitril is not used on its own. Inhibiting neprilysin alone would raise angiotensin II as well as natriuretic peptides, so it is formulated with valsartan to block the angiotensin receptor at the same time. All Cafoli formulations are therefore sacubitril/valsartan tablets, prescribed by cardiologists for heart failure with reduced ejection fraction.

You need a valid Drug License and a GST registration in your name. Once these are shared along with your territory preference, the Sacubitril franchise agreement and monopoly allotment can be processed.